Patents by Inventor Rachel Cohen-Kupiec

Rachel Cohen-Kupiec has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR MODIFYING THE GROWTH RATE OF A CELL
    Publication number: 20220098598
    Abstract: Genetically modified cells with at least one codon substituted to a synonymous codon, and with modified replicative fitness as compared to the unmodified cell, wherein a slower translating synonymous codon increases replicative fitness and a faster translating codon decreased replicative fitness are provided. Further, vaccine composition comprising those cells as well as methods for modifying replicative fitness of a cell are provided.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 31, 2022
    Inventors: Tamir TULLER, Hadas ZUR, Rachel COHEN-KUPIEC
  • Methods for modifying the growth rate of a cell
    Patent number: 11236344
    Abstract: Genetically modified cells with at least one codon substituted to a synonymous codon, and with modified replicative fitness as compared to the unmodified cell, wherein a slower translating synonymous codon increases replicative fitness and a faster translating codon decreased replicative fitness are provided. Further, vaccine composition comprising those cells as well as methods for modifying replicative fitness of a cell are provided.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: February 1, 2022
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Tamir Tuller, Hadas Zur, Rachel Cohen-Kupiec
  • METHODS FOR MODIFYING THE GROWTH RATE OF A CELL
    Publication number: 20180334679
    Abstract: Genetically modified cells with at least one codon substituted to a synonymous codon, and with modified replicative fitness as compared to the unmodified cell, wherein a slower translating synonymous codon increases replicative fitness and a faster translating codon decreased replicative fitness are provided. Further, vaccine composition comprising those cells as well as methods for modifying replicative fitness of a cell are provided.
    Type: Application
    Filed: May 21, 2018
    Publication date: November 22, 2018
    Inventors: Tamir Tuller, Hadas Zur, Rachel Cohen-Kupiec
  • Single chain antibodies against ?-amyloid peptide
    Patent number: 8221750
    Abstract: Anti-A?P scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of A?p 1-40 and disaggregate A?p 1-40 fibrils generated in vitro. The anti-A?p scFv antibodies also stained amyloid neuritic plaques on slices from transgenic mice. The anti-A?P scFv and single domain antibodies can be used for inhibiting or treating Alzheimer's disease.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: July 17, 2012
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Beka Solomon, Rachel Cohen-Kupiec
  • SINGLE CHAIN ANTIBODIES AGAINST BETA-AMYLOID PEPTIDE
    Publication number: 20120114650
    Abstract: Anti-A?P scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of A?p 1-40 and disaggregate A?p 1-40 fibrils generated in vitro. The anti-A?p scFv antibodies also stained amyloid neuritic plaques on slices from transgenic mice. The anti-A?P scFv and single domain antibodies can be used for inhibiting or treating Alzheimer's disease.
    Type: Application
    Filed: January 19, 2012
    Publication date: May 10, 2012
    Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Beka SOLOMON, Rachel Cohen-Kupiec
  • Single chain antibodies against ?-amyloid peptide
    Patent number: 8124076
    Abstract: Anti-A?P scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of Abp 1-40 and disaggregate Abp 1-40 fibrils generated in vitro. The anti-A?p scFv antibodies also stained amyloid neuritic plaques on slices from transgenic mice. The anti-A?P scFv and single domain antibodies can be used for inhibiting or treating Alzheimer's disease.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: February 28, 2012
    Assignee: Ramot At Tel Aviv University Ltd.
    Inventors: Beka Solomon, Rachel Cohen-Kupiec
  • FILAMENTOUS BACTERIOPHAGE DISPLAYING PROTEIN AS A BINDER OF ANTIBODIES AND IMMUNOCOMPLEXES FOR DELIVERY TO THE BRAIN
    Publication number: 20090317324
    Abstract: The present invention relates to a phage display vehicle composed of a filamentous bacteriophage displaying on its surface, as a non-filamentous bacteriophage molecule, protein A or a fragment or variant thereof capable of binding the Fc portion of antibodies, and an antibody or an antigen-antibody immunocomplex bound to protein A or a fragment or variant thereof by its Fc portion. The phage display vehicle is formulated into a pharmaceutical composition and can be used to treat/inhibit or to diagnose a brain disease, disorder or condition.
    Type: Application
    Filed: February 15, 2007
    Publication date: December 24, 2009
    Applicant: RAMOT at Tel Aviv University
    Inventors: Beka Solomon, Rachel Cohen Kupiec
  • SINGLE CHAIN ANTIBODIES AGAINST BETA-AMYLOID PEPTIDE
    Publication number: 20090186027
    Abstract: Anti-A?P scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of Abp 1-40 and disaggregate Abp 1-40 fibrils generated in vitro. The anti-A?p scFv antibodies also stained amyloid neuritic plaques on slices from transgenic mice. The anti-ABP scFv and single domain antibodies can be used for inhibiting or treating Alzheimer's disease.
    Type: Application
    Filed: August 18, 2006
    Publication date: July 23, 2009
    Applicant: Ramot AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Beka Solomon, Rachel Cohen-Kupiec